Not Signed In - [ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
Hepatitis B |
|
|
Clinical Trial: Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients with Chronic Hepatitis B
This study is currently recruiting patients.
Verified by Idenix Pharmaceuticals August 2005
|
Purpose
This study is being conducted to compare the effectiveness of the combination of valtorcitabine and telbivudine to telbivudine alone in patients with chronic hepatitis B.
| Condition | Intervention | Phase |
|---|---|---|
| Hepatitis B | Drug: telbivudine Drug: valtorcitabine | Phase II |
MedlinePlus related topics: Hepatitis B
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized, Blinded, Phase IIb Trial of Telbivudine (LdT) Versus the Combination of Telbivudine and Valtorcitabine (Val-LdC) in Patients with Chronic Hepatitis B
Eligibility
Ages Eligible for Study: 18 Years - 70 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Patient is pregnant or breastfeeding
- Patient is co-infected with hepatitis C virus, hepatitis D virus or HIV
- Patient has previously received lamivudine, adefovir dipivoxil or an investigational anti-HBV nucleoside or nucleotide at anytime.
Other protocol-defined inclusion criteria may apply.
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00128544
Keith Pietropaolo 617-995-9818 pietropaolo.keith@idenix.com
Hong Kong
Pokfulam, Hong Kong; Recruiting
New Zealand
Auckland, New Zealand; Recruiting
Singapore
Singapore, Singapore; Recruiting
More Information
Study ID Numbers: NV-02C-004
Last Updated: August 9, 2005
Record first received: August 8, 2005
ClinicalTrials.gov Identifier: NCT00128544
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-23
Last Updated: August 9, 2005
Record first received: August 8, 2005
ClinicalTrials.gov Identifier: NCT00128544
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-23
Resources
- Add Hepatitis B Vaccination to Your Back to School List (National Center for Infectious Diseases, CDC, OPHS, HHS)
- Advice for Parents (Hepatitis B Foundation)
email this page
print this page
bookmark this page
feedback on this page
